AUTHORS
Rachel Elizabeth Granberg, MD, MPH, Shalini Shenoy, MD2, Melissa Mavers, MD3, Kelsey Busken, MD, MSc4, Moyosoreoluwa M Laditan, MD5, Kristin E Zorn, MD6, Thomas Pfeiffer, MD7
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Introduction: High-risk pediatric AML that requires upfront allogeneic hematopoietic cell transplant (allo-HCT) is characterized by intrinsic, stem-cell-level resistance. In contrast, relapsed disease after standard chemotherapy is primarily driven by acquired resistance through clonal evolution. These mechanisms may result in differential susceptibility to transplant conditioning and graft-versus-leukemia effects. The prognostic significance of pre-HCT measurable residual disease (MRD) may therefore vary between individuals in first (CR1) and second complete remission (CR2). Pediatric data addressing this question are limited.
Methods: We performed a secondary analysis of a publicly available Center for International Blood and Marrow Transplant Research dataset (P-6238) including children with AML undergoing first allo-HCT between 2008–2019 using myeloablative conditioning. Overall survival (OS) and relapse-free survival (RFS) were estimated using the Kaplan-Meier method. Relapse was assessed using the cumulative incidence function with treatment-related mortality as a competing risk. Multivariable Cox proportional hazards regression analysis assessed the impact of MRD status in CR1 and CR2, adjusting for biologically relevant covariates including patient sex and age, comorbidity index, cytogenetics, graft type, conditioning type, and transplant era.
Results: The cohort comprised 865 children (52% male). Patient ages were: >10 years (49%), 3–10 years (26%), and <3 years (25%). Most received chemotherapy-based conditioning (67%). Umbilical cord blood (UCB) grafts (46%) were utilized most frequently, followed by bone marrow (BM) (38%) and peripheral blood stem cells (16%).
Outcomes were similar between patients transplanted in CR1 (n=554) and CR2 (n=311). With a median follow-up of 69 months, 3-year OS was 65.6% (95% CI, 61.4–69.5) vs 64.1% (95% CI, 58.4–69.3; p=0.9) and RFS was 55.9% (95% CI, 51.6–60.0) vs 56.9% (95% CI, 51.1–62.3; p=0.5). The corresponding 3-year cumulative incidence of relapse (CIR) was 31.4% (95% CI, 27.4–35.3) and 28.4% (95% CI, 23.3–33.4; p=0.25) with a median time to relapse of 6.1 and 7.4 months, respectively.
Next, we evaluated the prognostic impact of pre-transplant MRD status within each remission cohort separately. Baseline patient and treatment characteristics were well matched between MRD– and MRD+ groups in CR1 and CR2.
In the CR1 cohort, the 3-year CIR was 29.6% (95% CI, 25.1–34.0) and 36.8% (95% CI, 28.4–45.1) for MRD– (n=421) and MRD+ patients (n=133), respectively (p=0.069). MRD status did not appear to impact relapse in multivariable analysis (MVA, HR 1.37; p=0.072). Female sex (HR 0.63; p=0.004), UCB graft (vs BM; HR 0.67; p=0.028), and age ≥3 [3–10 years (HR 0.60; p=0.016); >10 years (HR 0.55; p=0.003)] were protective against relapse. Three-year RFS was 56.8% (95% CI, 51.8–61.5) for MRD– patients and 53.3% (95% CI, 44.3–61.5) for MRD+ patients (p=0.4). The corresponding 3-year OS was 65.2% (95% CI, 60.3–69.6) and 67.0% (95% CI, 58.1–74.3) (p>0.9). MVA confirmed no association between MRD status and RFS (HR 1.20; p=0.2) or OS (HR 1.05; p=0.8).
For patients in CR2, MRD status was a significant predictor of relapse. The 3-year CIR was 23.7% (95% CI, 18.3–29.1) for MRD– patients (n=245) compared to 45.5% (95% CI, 33.3–57.7) in MRD+ patients (n=66) (p=0.001). MVA confirmed that MRD+ patients had higher relapse risk (HR 2.28; p<0.001). Age >10 years (vs <3; HR 0.53; p=0.020) and UCB graft (vs BM; HR 0.63; p=0.049) were associated with reduced relapse risk. Three-year RFS was 61.3% (95% CI, 54.9–67.2) for MRD– patients and 40.8% (95% CI, 28.9–52.3) for MRD+ patients (p=0.008). The corresponding 3-year OS was 66.9% (95% CI, 60.5–72.5) and 54.1% (95% CI, 41.3–65.3) (p=0.11). In MVA, MRD+ status was associated with inferior RFS (HR 1.55; p=0.031) but not OS (HR 1.29; p=0.3).
Conclusion: In this largest-to-date retrospective analysis of 865 pediatric patients with AML undergoing allo-HCT, the prognostic significance of pre-HCT MRD differed between first and second remission. While MRD positivity was not significantly associated with OS, RFS, or CIR in CR1, CR2 patients with pre-HCT MRD+ disease had a significantly increased risk of relapse and inferior RFS. Patients in CR2 with MRD+ disease may therefore benefit from further optimization of disease burden pre-HCT or strategies to reduce relapse post-HCT, including donor lymphocyte infusion and/or maintenance chemotherapy.
DISCLOSURES
Rachel Elizabeth Granberg, MD, MPH: No relevant conflicts of interest to declare.